What Is AKI-D? Acute Kidney Injury Requiring Dialysis

AKI-D refers to acute kidney injury severe enough to require dialysis, a situation in which the kidneys fail so abruptly and completely that a machine must temporarily take over their blood-filtering work. It is among the most serious complications seen in hospitalized patients, with in-hospital death rates ranging from roughly 30% to nearly 47% depending on the population studied and the setting involved.¹² What makes AKI-D especially challenging is that it sits at the intersection of kidney care, critical care medicine, and long-term nephrology follow-up, and getting any one of those pieces wrong can change a patient’s trajectory for years.

What Causes AKI-D and How Common Is It

Acute kidney injury exists on a spectrum. Most cases are mild enough that the kidneys recover on their own with supportive care. AKI-D represents the far end of that spectrum, where toxin buildup, dangerous electrolyte levels, or severe fluid overload force clinicians to initiate some form of dialysis. Common triggers include sepsis (overwhelming infection), toxic exposures, cardiogenic shock, and flare-ups of underlying kidney disease.³ In many low- and middle-income settings, toxin ingestion and community-acquired infections dominate, while in high-income ICUs, sepsis and post-surgical complications tend to lead the list.

The incidence of AKI-D has been climbing in recent years. A nationwide French study found that cases rose from about 22,000 to over 25,000 hospital stays per year between 2009 and 2014, translating to an annual increase of roughly 1.7%.⁴ This upward trend likely reflects both aging populations with more comorbidities and broader recognition of the condition. In-hospital mortality in that study held steady at about 47%, with older age, delayed start of dialysis relative to admission, and ICU admission all independently tied to worse outcomes.

What Happens Inside the Kidneys

When AKI-D develops, the damage usually unfolds in phases. In the early phase, kidney cells begin dying through a process that triggers an intense inflammatory response. The immune system sends neutrophils, then macrophages, to the site of injury, and their activity can paradoxically worsen the damage by amplifying inflammation in the kidney tissue. Whether the kidneys eventually heal, stabilize at a reduced level of function, or continue deteriorating toward chronic kidney disease depends on how much of this initial injury resolves and how many functional units (nephrons) survive.⁵ The remaining nephrons have to work harder to compensate, and if the burden is too great, they can burn out over time. This is a key reason why even patients who come off dialysis after AKI-D still face elevated long-term kidney risk.

When Should Dialysis Start

Few questions in critical care nephrology have generated as much debate as when to hook up a patient with AKI to a dialysis machine. Intuitively, starting sooner seems like it should help, since toxins and excess fluid get cleared before they cause additional organ damage. But multiple large trials have found that early initiation does not improve survival compared with a more watchful strategy.

The STARRT-AKI trial, one of the largest on this question, randomized nearly 3,000 critically ill patients to either an accelerated or standard start. At 90 days, about 44% of patients in both groups had died, with virtually no difference between them. Patients who started dialysis earlier were actually more likely to still be dependent on it at 90 days (about 10% versus 6%) and experienced more adverse events.⁶ A separate French trial (IDEAL-ICU) found a similar pattern: 28-day mortality did not differ meaningfully between early and delayed groups.⁷

One earlier, smaller trial did find a survival benefit for early initiation, with 90-day mortality around 39% in the early group versus 55% in the delayed group.⁸ But this trial was much smaller (about 230 patients) and the results have not been replicated by the larger studies that followed. The prevailing view now is that a watchful approach is reasonable for most patients. Starting early exposes people who might have recovered on their own to unnecessary dialysis, with its associated complications like low blood pressure, infections from catheters, and potential delay in kidney recovery.

Types of Dialysis Used in AKI-D

Dialysis is not one thing. Patients with AKI-D may receive any of several modalities, and the choice depends on how stable they are, where they are being treated, and what resources are available.

Continuous therapies (CRRT): These run around the clock, pulling fluid and toxins slowly and steadily. They tend to be used for the sickest patients, particularly those with low blood pressure, because the gradual fluid removal is easier on the cardiovascular system.
Intermittent hemodialysis (IHD): Standard sessions lasting a few hours, typically three or more times a week. Better suited for patients who are hemodynamically stable.
Prolonged intermittent therapy (PIRRT): A hybrid that runs for six to twelve hours per session. It combines some of the gentleness of CRRT with the flexibility and lower cost of intermittent treatments.⁹
Peritoneal dialysis (PD): Fluid is cycled through the abdominal cavity, using the body’s own peritoneal membrane as a filter. It remains underutilized for AKI despite being simpler and cheaper, and in resource-limited settings it can be a lifeline when hemodialysis equipment is not available.¹⁰

A secondary analysis of the STARRT-AKI trial data found that patients who started on CRRT had lower odds of death or dialysis dependence at 90 days compared with those who began on intermittent hemodialysis, after adjusting for differences in baseline severity. The association was driven primarily by a lower rate of persistent dialysis dependence rather than a mortality difference.¹¹ This is not definitive proof that CRRT is superior, because sicker patients who receive CRRT also tend to get more attentive monitoring and different supportive care. But it does reinforce that modality choice is more than a logistical decision.

How Hard to Dialyze

A natural assumption is that filtering the blood more aggressively should produce better results. Multiple studies have tested this, and the answer is consistently that more is not better for the broad population. A large U.S. trial found no difference in 60-day mortality between intensive and less-intensive dialysis regimens for critically ill patients with AKI.¹² A systematic review pooling data across multiple trials confirmed this: higher-intensity dialysis did not reduce death or improve kidney recovery compared with standard dosing.¹³

There may be exceptions. One study found that among patients who did not have sepsis and were not severely oliguric (producing very little urine), higher-intensity dialysis was associated with better 30-day survival.¹⁴ This suggests the overall “no benefit” finding might mask subgroups who do better with more dialysis, but no large trial has confirmed this. For now, standard-dose dialysis remains the default approach.

Fluid Removal During Dialysis

Fluid overload is a major problem in AKI-D patients. When the kidneys stop making urine, every intravenous fluid, medication drip, and nutritional infusion adds to a growing surplus that can waterlog the lungs, strain the heart, and worsen organ failure. Dialysis offers a way to remove that excess through a process called ultrafiltration, but doing it too fast can crash blood pressure and further injure the kidneys.

A study of patients on continuous dialysis found that those whose fluid removal rate exceeded a certain threshold had lower 30-day mortality and fewer adverse kidney events at 90 days, suggesting that adequately addressing fluid overload matters.¹⁵ However, a separate study looking at intermittent hemodialysis sessions found no significant differences in kidney recovery or dialysis dependence at 90 days between higher and lower fluid removal groups.¹⁶ The emerging consensus is that moderate, carefully titrated fluid removal during continuous therapies is safest, and that aggressive removal should be avoided to minimize hemodynamic instability.¹⁷

Getting Off Dialysis

For patients who survive the acute phase, the critical next question is whether their kidneys will recover enough to stop dialysis. Recovery is not binary; some patients regain full function, others plateau at reduced levels, and some never get off the machine. Clinicians look for signs that the kidneys are waking up, with daily urine output above about 500 milliliters being a key threshold that prompts consideration of a weaning attempt.¹⁸

A meta-analysis of predictive factors for successful weaning identified several consistent signals: how long the patient had been on dialysis, their urine output around the time of the weaning attempt, and urinary creatinine levels all helped predict who could safely stop.¹⁹ A more recent study developed a scoring tool (called UNDERSCORE) that combined six variables, including whether the patient was still on a breathing machine or blood-pressure-supporting medications, to predict weaning success. Among patients who attempted weaning, about 56% were successfully freed from dialysis.²⁰

Researchers are also exploring urinary biomarkers that might predict kidney recovery further out. Uromodulin, a protein made by healthy kidney tubule cells, shows promise for predicting whether kidneys will recover at three months. A simpler ratio of urinary creatinine to urine osmolality may also be useful as a screening tool, which is appealing because it does not require specialized lab tests.²¹

Long-Term Kidney Risk After AKI-D

Surviving the hospital stay is not the end of the story. A Danish nationwide study followed ICU patients for five years and found that those who had AKI-D carried a dramatically higher risk of progressing to permanent kidney failure. In the first six months after ICU admission, about 8.5% of AKI-D survivors developed end-stage renal disease, compared with 0.1% of other ICU patients. Even among those who made it through the first six months without permanent kidney failure, the risk over the next four and a half years was still about 3.8%, compared with 0.3% for other ICU patients.²² The message is clear: even when AKI-D patients recover kidney function in the short term, close nephrology follow-up remains important for years.

The Rocky Transition to Outpatient Care

Patients who leave the hospital still dependent on dialysis face a notoriously messy handoff. Hospital electronic health records often do not communicate seamlessly with outpatient dialysis centers, which can lead to medication errors, missed appointments, and lost clinical context. Discharge summaries frequently lack critical kidney-specific details like what triggered the AKI, how much urine the patient was making at discharge, and what the plan is for reassessing kidney recovery.²³

A major part of the problem is that outpatient dialysis systems were built for patients with permanent kidney failure, not for people who might recover. There is a lack of standardized protocols for monitoring recovery, adjusting dialysis frequency, or deciding when to attempt stopping treatment in the outpatient setting.²⁴ Some patients are not even aware they had AKI or that recovery is possible, which means they may not advocate for themselves when it comes to weaning attempts. This is an area where care delivery lags well behind the science.

Drug Dosing Becomes a Guessing Game

Getting medications right in AKI-D patients is one of the trickiest problems in critical care pharmacy. The kidneys normally clear many drugs from the body, and when they stop working, drug levels can climb dangerously high. But dialysis also removes drugs, and different types of dialysis remove different amounts depending on the drug’s size, how tightly it binds to blood proteins, and whether the dialysis is continuous or intermittent. Adjusting doses requires accounting for what the patient’s residual kidneys are doing, what the machine is removing, and how sick the patient is, since critical illness itself changes how drugs distribute through the body.²⁵ Antibiotics are a particular concern because underdosing can fail to control infection while overdosing can cause seizures or other toxicity. There are no universally reliable formulas; most dosing decisions blend published guidelines with clinical judgment and, when available, direct measurement of drug levels in the blood.

Feeding AKI-D Patients

Critical illness ramps up the body’s metabolic demands, and dialysis compounds the problem by washing out amino acids and small proteins along with the toxins. Patients on continuous dialysis can lose roughly 10 to 15 grams of amino acids and 5 to 10 grams of protein per day through the filter. To compensate, expert consensus recommends providing at least 1.5 grams of protein per kilogram of body weight per day, and up to 2.5 grams per kilogram in patients on continuous therapies.²⁶ These numbers are substantially higher than what a healthy person needs, and they stand in contrast to the traditional advice of restricting protein in kidney disease. The distinction matters: in chronic kidney disease, limiting protein can slow progression, but in acute illness with active dialysis, underfeeding protein leads to muscle wasting and worse outcomes.

Quality of Life After Surviving AKI-D

Surviving AKI-D is a significant physical and emotional ordeal, and the effects linger well beyond hospital discharge. A study comparing AKI survivors to the general population found that physical health scores were substantially lower in the AKI group, and the gap persisted even after accounting for age, sex, and kidney function.²⁷ In a separate survey of AKI survivors, 84% described the experience as having a very or extremely significant impact on their physical and emotional health, and more than half reported serious concerns about its effects on their ability to work.²⁸

Factors that predicted better quality of life included younger age, absence of pre-existing chronic kidney disease, not having had sepsis during the acute illness, and shorter ICU and hospital stays.²⁹ Interestingly, the severity of the acute illness itself, measured by standard ICU scoring systems, did not directly predict quality of life. What mattered more was how quickly people got back to normal life activities afterward.

AKI-D in Children

Pediatric AKI-D is rarer than in adults but carries its own set of challenges. A ten-year retrospective study found that CRRT was the most commonly used modality in children (about 69% of cases), followed by intermittent hemodialysis (26%) and peritoneal dialysis (5%). Overall survival was about 45%, substantially lower than in many adult cohorts. Sepsis and the use of nephrotoxic drugs were the strongest independent predictors of death, while children whose AKI stemmed from primary kidney disease had much better outcomes.³⁰

A U.S. analysis of children, adolescents, and young adults found that intermittent hemodialysis was actually the most common modality overall (about 73% of encounters), with peritoneal dialysis at about 20% and CRRT at about 7%. In-hospital mortality was roughly 34%, and children under age two faced particularly high odds of death. Trends over the study period showed increasing use of CRRT and intermittent hemodialysis in inpatient settings, mirroring the adult shift toward more continuous approaches for sicker patients.³¹ Fluid overload at the time dialysis is started appears to be especially consequential in pediatric patients: in one study, children with fluid overload of 10% or greater had roughly double the mortality of those below that threshold.

The Financial Burden

AKI-D is among the most expensive acute conditions to manage. In U.S. hospitals, the incremental cost attributable to AKI requiring dialysis has been estimated at roughly $11,000 to $42,000 per hospitalization, with an average of nearly four additional hospital days compared with patients who do not develop AKI.³²³³ That range reflects wide variation in how the cost accounting is done and which patient populations are studied, but the direction is consistent: AKI-D substantially inflates hospital costs. These figures do not capture the downstream expenses of outpatient dialysis for patients who remain dependent, nephrology follow-up visits, or lost wages during recovery, all of which add to the economic toll for patients and health systems alike.

Anticoagulation During Continuous Dialysis

Continuous dialysis circuits tend to clot, which interrupts treatment and wastes expensive equipment. To prevent this, clinicians use anticoagulation strategies within the circuit. The most common approach in many ICUs is regional citrate anticoagulation, where citrate is infused into the blood entering the filter to bind calcium (which blood needs to clot) and then calcium is replaced after the blood returns to the patient. This keeps the circuit anticoagulated without thinning the patient’s blood systemically, which is important because many AKI-D patients are already at high bleeding risk.

Citrate is generally safe, but it can accumulate in patients with severe liver dysfunction because the liver is responsible for metabolizing it. A meta-analysis of studies in liver-failure patients found that citrate accumulation occurred in about 12% of cases and clinically significant bleeding in about 5%, while median filter lifespan reached roughly 56 hours.³⁴ Those numbers suggest citrate remains a reasonable choice even in patients with impaired liver function, though closer monitoring is warranted. The alternative, systemic heparin, carries its own risk of bleeding and the rare but dangerous complication of heparin-induced thrombocytopenia, making citrate the preferred first-line option in most centers that have experience with it.